GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » Gross Profit

TYRA (Tyra Biosciences) Gross Profit : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences Gross Profit?

Tyra Biosciences's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. Tyra Biosciences's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Tyra Biosciences's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. Tyra Biosciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Tyra Biosciences's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

Tyra Biosciences had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Tyra Biosciences Gross Profit Historical Data

The historical data trend for Tyra Biosciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences Gross Profit Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial - - - - -

Tyra Biosciences Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tyra Biosciences's Gross Profit

For the Biotechnology subindustry, Tyra Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyra Biosciences's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Gross Profit falls into.


;
;

Tyra Biosciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Tyra Biosciences's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Tyra Biosciences's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Tyra Biosciences's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Tyra Biosciences  (NAS:TYRA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tyra Biosciences had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Tyra Biosciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyra Biosciences Business Description

Traded in Other Exchanges
N/A
Address
2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Executives
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alan Fuhrman officer: Chief Financial Officer C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Todd Harris director, officer: Chief Executive Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Daniel Bensen officer: Chief Operating Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ali D. Fawaz officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alta Partners Nextgen Fund Ii, L.p. 10 percent owner 4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert J More director, 10 percent owner 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Melissa Mccracken director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008